BlackRock
ZBIO

BlackRock’s Zenas BioPharma ZBIO Stock Holding History

BlackRock’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$68.2M Buy
2,686,225
+648,677
+32% +$12.9M ﹤0.01% 2474
2026
Q1 		$39.8M Buy
2,037,548
+270,030
+15% +$6.06M ﹤0.01% 2660
2025
Q4 		$64.2M Buy
1,767,518
+538,877
+44% +$17.7M ﹤0.01% 2364
2025
Q3 		$27.3M Buy
1,228,641
+133,032
+12% +$2.17M ﹤0.01% 2897
2025
Q2 		$10.6M Buy
1,095,609
+81,499
+8% +$794K ﹤0.01% 3388
2025
Q1 		$8.01M Buy
1,014,110
+7,552
+0.8% +$59.1K ﹤0.01% 3430
2024
Q4 		$8.24M Buy
+1,006,558
New +$15.7M ﹤0.01% 3525

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $242M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock's ZBIO Position: Q2 2026 in Review

BlackRock increased its Zenas BioPharma (ZBIO) stake by 32% in Q2 2026, buying an estimated $12.9M and bringing the position to 2,686,225 shares worth $68.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2474.

BlackRock first reported a position in ZBIO in Q4 2024 and has held it in 7 quarters since. 144 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

  • BlackRock held 2,686,225 shares of Zenas BioPharma worth $68.2M as of Q2 2026.
  • BlackRock bought 648,677 Zenas BioPharma shares in Q2 2026, an estimated $12.9M.
  • Zenas BioPharma made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #2474 holding.
  • BlackRock first reported a position in Zenas BioPharma in Q4 2024 and has held it in 7 quarters since.
  • 144 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.